[Effect of peptide YY on hepatic fibrosis in rats].
OBJECTIVE
To investigate the therapeutic effects of peptide YY against hepatic fibrosis in rats and explore the possible mechanism.


METHODS
Rat models of hepatic fibrosis were established with a subcutaneous injection of carbon tetrachloride and randomized into normal control group, model group, peptide YY (PYY)-treated group, octreotide-treated group, and interferon gamma-treated group. Serum levels of the hepatic function indices and hepatic fibrotic index were detected, and the hepatic fibrosis grade was assessed using HE staining. The expression of transforming growth factor beta1 (TGFbeta1) were determined with immunohistochemical staining method.


RESULTS
The rats in PYY-treated group showed significantly different serum levels of TBIL, HA and LN from the rats in the model group (P<0.05). PYY significantly reduced hepatic fibrosis scores and lowered TGFbeta1 expression as compared with the model group.


CONCLUSIONS
PYY can down-regulate TGFbeta1 expression to inhibit the development of hepatic fibrosis with comparable efficacy with interferon gamma and octreotide.
Song
Dan-ping
DP
Department of Gastroenterology, Second Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Dong
Lei
L
D000818:Animals; D002251:Carbon Tetrachloride; D007150:Immunohistochemistry; D008106:Liver Cirrhosis, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D019894:Peptide YY / Q000627:therapeutic use*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D053773:Transforming Growth Factor beta1 / Q000096:biosynthesis*
C508962:Tgfb1 protein, rat; D053773:Transforming Growth Factor beta1; D019894:Peptide YY; D002251:Carbon Tetrachloride